A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Recruiting now · Phase 1

Conditions studied: Advanced Breast Cancer

In brief

The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).

Key facts

Study ID

NCT07310420

Run by

TerSera Therapeutics LLC

People needed

88

Starts

2026-08-30

Expected to finish

2027-03-30

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older, up to 55. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age and gender:
• Gonadotropin-releasing Hormone (GnRH) treatment-naïve: Female participants aged 18 to 55 years, inclusive.
• GnRH treatment-exposed <6 months: Female participants aged 18 to 55 years, inclusive, if GnRH treatment started within <6 months of signing the informed consent.
• Advanced or metastatic breast cancer: Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent per investigator's assessment.
• HR+: Either estrogen receptor positive (ER+) or progesterone receptor positive (PR+) breast cancer, defined as 1% to 100% of tumor nuclei are positive for ER or PR via immunohistochemistry.
• HER2-: Via American Society of Clinical Oncology, College of American Pathology (ASCO-CAP) guidelines.
• Prior treatment:
• Participants may have received prior radiotherapy.
• Participants may have received or be receiving a cyclin-dependent kinase (CDK) 4/6 inhibitor, a phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha-protein kinase B (PIK3CA-AKT) inhibitor, or bisphosphonates if initiated and at a stable dose for at least 2 weeks before trial enrollment.
• GnRH treatment-naïve participants will have no history of GnRH agonist or other endocrine therapy in the advanced/metastatic setting.
• GnRH treatment-exposed participants may have received a GnRH agonist or other endocrine therapy provided they had established premenopausal status prior to initiating GnRH agonist therapy, within 6 months prior to trial enrollment.
• Chemotherapy History:
• a. A participant may have received adjuvant or neoadjuvant chemotherapy in early-stage breast cancer.
• i. Any participant who received prior adjuvant or neoadjuvant chemotherapy are eligible provided the criteria for premenopausal status.
• b. All chemotherapy-related toxicities must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) v6.0 ≤Grade 1 before trial participation, except for alopecia, peripheral neuropathy, or paresthesia (≤Grade 2).
• Concurrent Medications:
• Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are permitted if initiated and tolerated without ongoing toxicity CTCAE v6.0 >Grade 1 for at least 2 weeks before trial enrollment.
• PIK3CA/AKT inhibitors are permitted if started at least 2 weeks before the trial and tolerated without ongoing toxicity CTCAE v6.0 >Grade 1.
• Concomitant use of bisphosphonates is permitted if initiated and tolerated without ongoing toxicity CTCAE v6.0 >Grade 1 for at least 2 weeks before trial enrollment.
• Concomitant use of endocrine therapy (eg, aromatase inhibitor, fulvestrant, or other FDA-approved selective estrogen receptor degraders [SERDs]) is permitted.
• Informed consent: Able to understand and willing to provide informed consent and able to comply with the trial procedures and restrictions.
• Contraceptive use: Female participants may be enrolled if they are:
• Practicing true abstinence for at least 28 days prior to investigational product (IP) administration until 30 days after the last IP administration and having a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day -1, OR
• Using 2 forms of highly effective nonhormonal contraception, including 1 physical barrier (condom or diaphragm) plus another nonhormonal method (eg, intrauterine device, spermicidals) from Screening or at least 2 weeks prior to IP administration (whichever is earlier) until 30 days after the last IP administration and having a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day -1.
• Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

You may not qualify if…

• Postmenopausal: Naturally or surgically postmenopausal (regardless of age).
• Body mass index (BMI): <18 kg/m\^2 or >35.0 kg/m\^2.
• Prior surgical or radiation procedures: History of bilateral oophorectomy or prior radiotherapy to the ovaries.
• Recent radiotherapy:
• Radiotherapy for breast cancer within 4 weeks prior to trial enrollment.
• All radiotherapy-related toxicities (except alopecia) must have recovered to CTCAE v6.0 ≤Grade 1 before trial enrollment.
• Radiotherapy during trial: Planned radiotherapy during trial period.
• Selective estrogen receptor modulator (SERM) use during trial: Participants may not receive tamoxifen or other SERMs during the trial and must discontinue any SERMs prior to enrollment, other endocrine therapies (eg, aromatase inhibitor, fulvestrant, or other FDA-approved SERDs) are allowed.
• Hypersensitivity: Known hypersensitivity, idiosyncratic, or allergic reactions to goserelin, GnRH, GnRH agonists/analogs, or any trial drug components.
• Expected survival: Estimated life expectancy <6 months from the start of trial therapy, based on the principal investigator's (PI) clinical judgment.
• Performance status: ECOG performance status ≥3.
• Life-threatening disease or metastasis: Presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement, symptomatic pulmonary lymphangitic spread, symptomatic pleural disease, or any symptomatic brain/leptomeningeal metastases (proven or suspected). Participants with asymptomatic or stable/treated brain metastases are eligible to enroll if neurologically stable and are receiving a stable or decreasing corticosteroid dose at the time of enrollment. Participants with discrete pulmonary parenchymal metastases are eligible if respiratory function is not compromised.
• Hepatic function:
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2×upper limit of normal (ULN) if no liver metastases, or >5×ULN with liver metastases.
• Total bilirubin ≥1.5×ULN (≥2.5×ULN for Gilbert's syndrome).
• Renal function: Creatinine clearance (CrCl) ≤30 mL/min as calculated by the Cockcroft-Gault formula.
• Hematologic parameters:
• Hemoglobin (Hgb) <8.0 g/dL.
• White blood cell (WBC) count <3000/mm\^3.
• Platelets <100,000/mm\^3.
• Other malignancies: Active malignancy within the past 3 years, except for adequately treated basal or squamous cell skin cancer or in situ cervical carcinoma.
• Concurrent medical conditions: Presence of any severe, uncontrolled, or serious illness, medical condition (including psychiatric/addictive disorders), or clinical finding that could compromise trial adherence, as assessed by the investigator.
• Investigational drug exposure: Exposure to any investigational drug or device within 30 days prior to trial enrollment.
• Pregnancy: Participant has childbearing potential with a positive serum pregnancy test or positive urine pregnancy test at Screening or Day 1.
• Breastfeeding: Participant is currently breastfeeding.

Where it is running

• Genesis Cancer and Blood Institute — Hot Springs, Arkansas, United States (enrolling)
• MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center — Washington D.C., District of Columbia, United States (enrolling)
• Cancer Centers of Florida — Ocoee, Florida, United States (enrolling)
• Summit Cancer Care — Savannah, Georgia, United States (enrolling)
• NorthShore University Health System - Evanston Hospital — Evanston, Illinois, United States (enrolling)
• NorthShore University HealthSystem - Evanston Hospital — Evanston, Illinois, United States (enrolling)
• Duly Health and Care — Lisle, Illinois, United States (enrolling)
• Orchard Healthcare Research — Skokie, Illinois, United States (enrolling)
• Springfield Clinic - The Cancer Center — Springfield, Illinois, United States (enrolling)
• Profound Research LLC at Michigan Hematology and Oncology Consultants — Royal Oak, Michigan, United States (enrolling)
• St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute) — Billings, Montana, United States (enrolling)
• San Juan Oncology Associates — Farmington, New Mexico, United States (enrolling)
• New York Oncology Hematology - Amsterdam Cancer Center — Amsterdam, New York, United States (enrolling)
• Montefiore Medical Center — East Syracuse, New York, United States (enrolling)
• Chelsea Medical Center at Mount Sinai — New York, New York, United States (enrolling)
• Cleveland Clinic Foundation — Cleveland, Ohio, United States (enrolling)
• The Mark H. Zangmeister Center-Mid Ohio Oncology/Hematology, Inc. — Columbus, Ohio, United States (enrolling)
• St. Luke's University Health Network — Bethlehem, Pennsylvania, United States (enrolling)
• Guthrie Medical Group — Sayre, Pennsylvania, United States (enrolling)
• Oncology Consultants PA — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.